FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3171520007> ?p ?o ?g. }

• W3171520007 endingPage "136" @default.
• W3171520007 startingPage "136" @default.
• W3171520007 abstract "<ns3:p><ns3:bold>Background:</ns3:bold> Tuberculous meningitis (TBM) is the most lethal form of tuberculosis with a mortality of ~50% in those co-infected with HIV-1. Current antibiotic regimens are based on those known to be effective in pulmonary TB and do not account for the differing ability of the drugs to penetrate the central nervous system (CNS). The host immune response drives pathology in TBM, yet effective host-directed therapies are scarce. There is sufficient data to suggest that higher doses of rifampicin (RIF), additional linezolid (LZD) and adjunctive aspirin (ASA) will be beneficial in TBM yet rigorous investigation of the safety of these interventions in the context of HIV associated TBM is required. We hypothesise that increased dose RIF, LZD and ASA used in combination and in addition to standard of care for the first 56 days of treatment with be safe and tolerated in HIV-1 infected people with TBM.</ns3:p><ns3:p> <ns3:bold>Methods:</ns3:bold> In an open-label randomised parallel study, up to 100 participants will receive either; i) standard of care (n=40, control arm), ii) standard of care plus increased dose RIF (35mg/kg) and LZD (1200mg OD for 28 days, 600mg OD for 28 days) (n=30, experimental arm 1), or iii) as per experimental arm 1 plus additional ASA 1000mg OD (n=30, experimental arm 2). After 56 days participants will continue standard treatment as per national guidelines. The primary endpoint is death and the occurrence of solicited treatment-related adverse events at 56 days. In a planned pharmacokinetic (PK) sub-study we aim to assess PK/pharmacodynamic (PD) of oral vs IV rifampicin, describe LZD and RIF PK and cerebrospinal fluid concentrations, explore PK/PD relationships, and investigate drug-drug interactions between LZD and RIF. Safety and pharmacokinetic data from this study will inform a planned phase III study of intensified therapy in TBM.</ns3:p><ns3:p> <ns3:bold><ns3:ext-link xmlns:ns4=http://www.w3.org/1999/xlink ext-link-type=uri ns4:href=http://Clinicaltrials.gov>Clinicaltrials.gov</ns3:ext-link> registration: </ns3:bold>NCT03927313 (25/04/2019)</ns3:p>" @default.
• W3171520007 created "2021-06-22" @default.
• W3171520007 creator A5003947650 @default.
• W3171520007 creator A5003971032 @default.
• W3171520007 creator A5009435222 @default.
• W3171520007 creator A5010890227 @default.
• W3171520007 creator A5011360930 @default.
• W3171520007 creator A5012198800 @default.
• W3171520007 creator A5015485726 @default.
• W3171520007 creator A5020333045 @default.
• W3171520007 creator A5020505440 @default.
• W3171520007 creator A5021539154 @default.
• W3171520007 creator A5025074716 @default.
• W3171520007 creator A5028422957 @default.
• W3171520007 creator A5029089921 @default.
• W3171520007 creator A5031461679 @default.
• W3171520007 creator A5034322602 @default.
• W3171520007 creator A5035388858 @default.
• W3171520007 creator A5035439157 @default.
• W3171520007 creator A5035638116 @default.
• W3171520007 creator A5038086852 @default.
• W3171520007 creator A5038184628 @default.
• W3171520007 creator A5039366424 @default.
• W3171520007 creator A5049487404 @default.
• W3171520007 creator A5051172388 @default.
• W3171520007 creator A5052193814 @default.
• W3171520007 creator A5056871445 @default.
• W3171520007 creator A5056892721 @default.
• W3171520007 creator A5061146630 @default.
• W3171520007 creator A5063879133 @default.
• W3171520007 creator A5064847379 @default.
• W3171520007 creator A5066195834 @default.
• W3171520007 creator A5070358573 @default.
• W3171520007 creator A5075475824 @default.
• W3171520007 creator A5077892502 @default.
• W3171520007 creator A5078231546 @default.
• W3171520007 creator A5079952907 @default.
• W3171520007 creator A5085468598 @default.
• W3171520007 creator A5086804222 @default.
• W3171520007 creator A5090394540 @default.
• W3171520007 date "2021-06-01" @default.
• W3171520007 modified "2023-10-18" @default.
• W3171520007 title "Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]" @default.
• W3171520007 cites W1949762636 @default.
• W3171520007 cites W1964291085 @default.
• W3171520007 cites W1969661146 @default.
• W3171520007 cites W1975757989 @default.
• W3171520007 cites W2004815652 @default.
• W3171520007 cites W2015536257 @default.
• W3171520007 cites W2015698893 @default.
• W3171520007 cites W2020129732 @default.
• W3171520007 cites W2023382034 @default.
• W3171520007 cites W2033728760 @default.
• W3171520007 cites W2055717177 @default.
• W3171520007 cites W2059786204 @default.
• W3171520007 cites W2067395123 @default.
• W3171520007 cites W2067811706 @default.
• W3171520007 cites W2077893909 @default.
• W3171520007 cites W2082850379 @default.
• W3171520007 cites W2101988363 @default.
• W3171520007 cites W2102697636 @default.
• W3171520007 cites W2103158311 @default.
• W3171520007 cites W2108960489 @default.
• W3171520007 cites W2109938551 @default.
• W3171520007 cites W2111947696 @default.
• W3171520007 cites W2112808847 @default.
• W3171520007 cites W2114110528 @default.
• W3171520007 cites W2115686919 @default.
• W3171520007 cites W2120074558 @default.
• W3171520007 cites W2120778013 @default.
• W3171520007 cites W2122198633 @default.
• W3171520007 cites W2128529067 @default.
• W3171520007 cites W2129441585 @default.
• W3171520007 cites W2134654586 @default.
• W3171520007 cites W2140603169 @default.
• W3171520007 cites W2140809531 @default.
• W3171520007 cites W2143942591 @default.
• W3171520007 cites W2148205948 @default.
• W3171520007 cites W2150492824 @default.
• W3171520007 cites W2151102304 @default.
• W3171520007 cites W2154439517 @default.
• W3171520007 cites W2163117709 @default.
• W3171520007 cites W2165758561 @default.
• W3171520007 cites W2167660959 @default.
• W3171520007 cites W2168509294 @default.
• W3171520007 cites W2168600901 @default.
• W3171520007 cites W2189726121 @default.
• W3171520007 cites W2316721031 @default.
• W3171520007 cites W2327564484 @default.
• W3171520007 cites W2333921168 @default.
• W3171520007 cites W2467247336 @default.
• W3171520007 cites W2516938750 @default.
• W3171520007 cites W2543303947 @default.
• W3171520007 cites W2554692247 @default.
• W3171520007 cites W2745915767 @default.
• W3171520007 cites W2788679213 @default.
• W3171520007 cites W2980057666 @default.
• W3171520007 cites W3009599329 @default.

• next